Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
暂无分享,去创建一个
Xiayang Qiu | David J Payne | M. Head | C. Janson | C. Yuan | D. Heerding | D. Payne | I. Uzinskas | P. Keller | X. Qiu | W. Miller | W. Huffman | K. Newlander | Martha S Head | Cheryl A Janson | S. Rittenhouse | W. deWolf | Paul M Keller | Dirk A Heerding | Stephen F Rittenhouse | William H Miller | Mark A Seefeld | Kenneth A Newlander | Irene N Uzinskas | Walter J Burgess | Catherine C K Yuan | Terrance D Moore | Stewart C Pearson | Valerie Berry | Walter E DeWolf | Brian J Polizzi | William F Huffman | V. Berry | W. J. Burgess | T. Moore | S. Pearson | B. Polizzi | M. Seefeld
[1] H. Bergler,et al. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA. , 1996, European journal of biochemistry.
[2] R J Heath,et al. Lipid biosynthesis as a target for antibacterial agents. , 2001, Progress in lipid research.
[3] Y. Luo,et al. Enoyl-ACP reductase (FabI) of Haemophilus influenzae: steady-state kinetic mechanism and inhibition by triclosan and hexachlorophene. , 2001, Archives of Biochemistry and Biophysics.
[4] R. Heath,et al. Broad Spectrum Antimicrobial Biocides Target the FabI Component of Fatty Acid Synthesis* , 1998, The Journal of Biological Chemistry.
[5] L. Katz,et al. New Directions in Antibacterial Research , 1997 .
[6] J. R. Brooks,et al. AZASTEROIDS AS INHIBITORS OF RAT PROSTATIC 5α-REDUCTASE , 1985 .
[7] D. D. Jaworski,et al. Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus. , 2001, The Journal of antimicrobial chemotherapy.
[8] S. Abdel-Meguid,et al. Molecular basis for triclosan activity involves a flipping loop in the active site , 2008, Protein science : a publication of the Protein Society.
[9] S. Levy,et al. Triclosan targets lipid synthesis , 1998, Nature.
[10] R. Lyons,et al. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. , 2001, International journal for parasitology.
[11] Axel T. Brunger,et al. X-PLOR Version 3.1: A System for X-ray Crystallography and NMR , 1992 .
[12] Antoni R. Slabas,et al. A Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase , 1996, Science.
[13] C. Janson,et al. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). , 2001, Bioorganic & medicinal chemistry letters.
[14] J. Brewster,et al. Dehydrations with Aromatic Sulfonyl Halides in Pyridine.1 A Convenient Method for the Preparation of Esters , 1955 .
[15] R J Heath,et al. Mechanism of Triclosan Inhibition of Bacterial Fatty Acid Synthesis* , 1999, The Journal of Biological Chemistry.
[16] R. Heck. PALLADIUM-CATALYZED VINYLATION OF ORGANIC HALIDES , 1983 .
[17] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[18] R. Heath,et al. The Enoyl-[acyl-carrier-protein] Reductases FabI and FabL fromBacillus subtilis * , 2000, The Journal of Biological Chemistry.
[19] D W Rice,et al. Mechanism of action of diazaborines. , 1998, Biochemical pharmacology.
[20] D. Rice,et al. Crystallographic analysis of triclosan bound to enoyl reductase. , 1999, Journal of molecular biology.
[21] I. Taylor,et al. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. , 1999, Biochemistry.
[22] P. Warren,et al. Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. , 2001, Drug discovery today.
[23] J. Verhoef,et al. The millennium bugs--the need for and development of new antibacterials. , 2000, International journal of antimicrobial agents.
[24] E. Setti,et al. CURRENT APPROACHES TO OVERCOME BACTERIAL RESISTANCE , 1997 .
[25] R. Heath,et al. Inhibition of the Staphylococcus aureusNADPH-dependent Enoyl-Acyl Carrier Protein Reductase by Triclosan and Hexachlorophene* , 2000, The Journal of Biological Chemistry.
[26] Martha S. Head,et al. Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents , 2002, Antimicrobial Agents and Chemotherapy.
[27] C. E. Peishoff,et al. Potent non-peptide fibrinogen receptor antagonists which present an alternative pharmacophore. , 1995, Journal of medicinal chemistry.
[28] R. Heath,et al. Enoyl-Acyl Carrier Protein Reductase (fabI) Plays a Determinant Role in Completing Cycles of Fatty Acid Elongation in Escherichia coli(*) , 1995, The Journal of Biological Chemistry.
[29] Charles O. Rock,et al. erratum: A triclosan-resistant bacterial enzyme , 2000, Nature.
[30] J. W. Campbell,et al. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. , 2001, Annual review of microbiology.
[31] N. Surolia,et al. Structural basis for triclosan and NAD binding to enoyl-ACP reductase of Plasmodium falciparum. , 2001, Biochemical and biophysical research communications.
[32] Antoni R. Slabas,et al. Molecular basis of triclosan activity , 1999, Nature.
[33] P. McDermott,et al. Genetic Evidence that InhA of Mycobacterium smegmatis Is a Target for Triclosan , 1999, Antimicrobial Agents and Chemotherapy.
[34] C. E. Peishoff,et al. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists. , 1996, Journal of medicinal chemistry.